Full Text View
Tabular View
No Study Results Posted
Related Studies
Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer
This study has been completed.
Study NCT00055770   Information provided by National Cancer Institute (NCI)
First Received: March 6, 2003   Last Updated: February 25, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Head and Neck Cancer
Additional conditions recognized in this trial
Carcinoma, Squamous Cell
Head and Neck Neoplasms
More general conditions related to this trial
Carcinoma
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Neoplasms, Squamous Cell
Interventions listed in this trial
docetaxel
erlotinib hydrochloride
Additional drug interventions recognized in this trial
Erlotinib
More general drug interventions related to this trial
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Kinase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Arthur G. James Cancer Hospital &Richard J. Solove Research Institute
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services